Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia.

ABSTRACT: Acute Myeloid Leukemia (AML) is the second most common type of leukemia in children. Recent advances in high-resolution genomic profiling techniques have uncovered the mutational landscape of pediatric AML as distinct from adult AML. Overall survival rates of children with AML have dramatically improved in the past 40 years, currently reaching 70% to 80% in developed countries. This was accomplished by the intensification of conventional chemotherapy, improvement in risk stratification using leukemia-specific cytogenetics/molecular genetics and measurable residual disease, appropriate use of allogeneic hematopoietic stem cell transplantation, and improvement in supportive care. However, the principle therapeutic approach for pediatric AML has not changed substantially for decades and impro

SUBMITTER: Tomizawa D 

PROVIDER: S-EPMC10452723 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature